Search

Your search keyword '"Cianniello, Daniela"' showing total 28 results
Start Over Author "Cianniello, Daniela"
28 results on '"Cianniello, Daniela"'

1. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

Author

Caputo, Roberta, primary, Buono, Giuseppe, additional, Piezzo, Michela, additional, Martinelli, Claudia, additional, Cianniello, Daniela, additional, Rizzo, Alessandro, additional, Pantano, Francesco, additional, Staropoli, Nicoletta, additional, Cangiano, Rodolfo, additional, Turano, Salvatore, additional, Paris, Ida, additional, Nuzzo, Francesco, additional, Fabi, Alessandra, additional, and De Laurentiis, Michelino, additional

Published
2024
Full Text
View/download PDF

2. PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Author

Cognetti, Francesco, Masetti, Riccardo, Fabi, Alessandra, Bianchi, Giulia, Santini, Donatella, Rognone, Alessia, Catania, Giovanna, Angelucci, Domenico, Naso, Giuseppe, Giuliano, Mario, Vassalli, Lucia, Vici, Patrizia, Scognamiglio, Giovanni, Generali, Daniele, Zambelli, Alberto, Colleoni, Marco, Tinterri, Corrado, Scanzi, Francesco, Vigna, Leonardo, Scavina, Paola, Gamucci, Teresa, Marrazzo, Emilia, Scinto, Angelo Fedele, Berardi, Rossana, Fabbri, Maria Agnese, Pinotti, Graziella, Franco, Daniela, Terribile, Daniela Andreina, Tonini, Giuseppe, Cianniello, Daniela, and Barni, Sandro

Published
2021
Full Text
View/download PDF

3. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion

Author

Caputo, Roberta, primary, Buono, Giuseppe, additional, Lauro, Vincenzo Di, additional, Cianniello, Daniela, additional, Arx, Claudia Von, additional, Pensabene, Matilde, additional, Pagliuca, Martina, additional, Pacilio, Carmen, additional, Rella, Francesca Di, additional, Verrazzo, Annarita, additional, Martinelli, Claudia, additional, Nuzzo, Francesco, additional, and Laurentiis, Michelino De, additional

Published
2023
Full Text
View/download PDF

4. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results

Author

De Placido, Sabino, Giuliano, Mario, Schettini, Francesco, Von Arx, Claudia, Buono, Giuseppe, Riccardi, Ferdinando, Cianniello, Daniela, Caputo, Roberta, Puglisi, Fabio, Bonotto, Marta, Fabi, Alessandra, Bilancia, Domenico, Ciccarese, Mariangela, Lorusso, Vito, Michelotti, Andrea, Bruzzese, Dario, Veneziani, Bianca Maria, Locci, Mariavittoria, De Laurentiis, Michelino, and Arpino, Grazia

Published
2018
Full Text
View/download PDF

5. Correction: Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial

Author

Porciello, Giuseppe, primary, Montagnese, Concetta, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, Libra, Massimo, additional, Vitale, Sara, additional, Palumbo, Elvira, additional, Pica, Rosa, additional, Calabrese, Ilaria, additional, Cubisino, Serena, additional, Falzone, Luca, additional, Poletto, Luigina, additional, Martinuzzo, Valentina, additional, Prete, Melania, additional, Esindi, Nadia, additional, Thomas, Guglielmo, additional, Cianniello, Daniela, additional, Pinto, Monica, additional, De Laurentiis, Michelino, additional, Pacilio, Carmen, additional, Rinaldo, Massimo, additional, D’Aiuto, Massimiliano, additional, Serraino, Diego, additional, Massarut, Samuele, additional, Evangelista, Chiara, additional, Steffan, Agostino, additional, Catalano, Francesca, additional, Banna, Giuseppe L., additional, Scandurra, Giuseppa, additional, Ferraù, Francesco, additional, Rossello, Rosalba, additional, Antonelli, Giovanna, additional, Guerra, Gennaro, additional, Farina, Amalia, additional, Messina, Francesco, additional, Riccardi, Gabriele, additional, Gatti, Davide, additional, Jenkins, David J. A., additional, Minopoli, Anita, additional, Grilli, Bruna, additional, Cavalcanti, Ernesta, additional, Celentano, Egidio, additional, Botti, Gerardo, additional, Montella †, Maurizio, additional, and Augustin, Livia S. A., additional

Published
2021
Full Text
View/download PDF

6. Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

Author

Piezzo, Michela, primary, D’Aniello, Roberta, additional, Avallone, Ilaria, additional, Barba, Bruno, additional, Cianniello, Daniela, additional, Cocco, Stefania, additional, D’Avino, Antonio, additional, Di Gioia, Germira, additional, Di Lauro, Vincenzo, additional, Fusco, Giuseppina, additional, Piscitelli, Raffaele, additional, von Arx, Claudia, additional, De Laurentiis, Michelino, additional, and Maiolino, Piera, additional

Published
2021
Full Text
View/download PDF

7. Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications

Author

Montagnese, Concetta, primary, Porciello, Giuseppe, additional, Vitale, Sara, additional, Palumbo, Elvira, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, Calabrese, Ilaria, additional, Pica, Rosa, additional, Prete, Melania, additional, Falzone, Luca, additional, Libra, Massimo, additional, Cubisino, Serena, additional, Poletto, Luigina, additional, Martinuzzo, Valentina, additional, Coluccia, Sergio, additional, Esindi, Nadia, additional, Nocerino, Flavia, additional, Minopoli, Anita, additional, Grilli, Bruna, additional, Fiorillo, Pasqualina C., additional, Cuomo, Marco, additional, Cavalcanti, Ernesta, additional, Thomas, Guglielmo, additional, Cianniello, Daniela, additional, Pinto, Monica, additional, De Laurentiis, Michelino, additional, Pacilio, Carmen, additional, Rinaldo, Massimo, additional, D'Aiuto, Massimiliano, additional, Serraino, Diego, additional, Massarut, Samuele, additional, Caggiari, Laura, additional, Evangelista, Chiara, additional, Steffan, Agostino, additional, Catalano, Francesca, additional, Banna, Giuseppe L., additional, Scandurra, Giuseppa, additional, Ferraù, Francesco, additional, Rossello, Rosalba, additional, Antonelli, Giovanna, additional, Guerra, Gennaro, additional, Farina, Amalia, additional, Messina, Francesco, additional, Riccardi, Gabriele, additional, Gatti, Davide, additional, Jenkins, David J. A., additional, Celentano, Egidio, additional, Botti, Gerardo, additional, and Augustin, Livia S. A., additional

Published
2020
Full Text
View/download PDF

8. Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial

Author

Porciello, Giuseppe, primary, Montagnese, Concetta, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, Libra, Massimo, additional, Vitale, Sara, additional, Palumbo, Elvira, additional, Pica, Rosa, additional, Calabrese, Ilaria, additional, Cubisino, Serena, additional, Falzone, Luca, additional, Poletto, Luigina, additional, Martinuzzo, Valentina, additional, Prete, Melania, additional, Esindi, Nadia, additional, Thomas, Guglielmo, additional, Cianniello, Daniela, additional, Pinto, Monica, additional, Laurentiis, Michelino De, additional, Pacilio, Carmen, additional, Rinaldo, Massimo, additional, D’Aiuto, Massimiliano, additional, Serraino, Diego, additional, Massarut, Samuele, additional, Evangelista, Chiara, additional, Steffan, Agostino, additional, Catalano, Francesca, additional, Banna, Giuseppe L., additional, Scandurra, Giuseppa, additional, Ferraù, Francesco, additional, Rossello, Rosalba, additional, Antonelli, Giovanna, additional, Guerra, Gennaro, additional, Farina, Amalia, additional, Messina, Francesco, additional, Riccardi, Gabriele, additional, Gatti, Davide, additional, Jenkins, David J. A., additional, Minopoli, Anita, additional, Grilli, Bruna, additional, Cavalcanti, Ernesta, additional, Celentano, Egidio, additional, Botti, Gerardo, additional, Montella, Maurizio, additional, and Augustin, Livia S. A., additional

Published
2020
Full Text
View/download PDF

9. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

Author

Piezzo, Michela, primary, Cocco, Stefania, additional, Caputo, Roberta, additional, Cianniello, Daniela, additional, Gioia, Germira Di, additional, Lauro, Vincenzo Di, additional, Fusco, Giuseppina, additional, Martinelli, Claudia, additional, Nuzzo, Francesco, additional, Pensabene, Matilde, additional, and Laurentiis, Michelino De, additional

Published
2020
Full Text
View/download PDF

10. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Author

Piezzo, Michela, primary, Chiodini, Paolo, additional, Riemma, Maria, additional, Cocco, Stefania, additional, Caputo, Roberta, additional, Cianniello, Daniela, additional, Di Gioia, Germira, additional, Di Lauro, Vincenzo, additional, Rella, Francesca Di, additional, Fusco, Giuseppina, additional, Iodice, Giovanni, additional, Nuzzo, Francesco, additional, Pacilio, Carmen, additional, Pensabene, Matilde, additional, and Laurentiis, Michelino De, additional

Published
2020
Full Text
View/download PDF

13. Effect of a low glycemic index Mediterranean diet on cardiovascular risk factors in women diagnosed with breast cancer: Preliminary data from DEDiCa study

Author

Calabrese, Ilaria, primary, Porciello, Giuseppe, additional, Montagnese, Concetta, additional, Vitale, Sara, additional, Palumbo, Elvira, additional, Cubisino, Serena, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, Pica, Rosita, additional, Marotta, Vincenzo, additional, Falzone, Luca, additional, Dainotta, Patrizia, additional, De Laurentis, Michele, additional, D'Aiuto, Massimiliano, additional, Rinaldo, Massimo, additional, Thomas, Guglielmo, additional, Catalano, Francesca, additional, Banna, Giuseppe, additional, Ursino, Vera, additional, Ferraù, Francesco, additional, Rossello, Rosalba, additional, Serraino, Diego, additional, Bidoli, Ettore, additional, Massarut, Samuele, additional, Barchiesi, Vittoria, additional, Minopoli, Anita, additional, Cuomo, Marco, additional, Cavalcanti, Ernesta, additional, Cianniello, Daniela, additional, Pacilio, Carmen, additional, Guerra, Gennaro, additional, Farina, Amalia, additional, Messina, Francesco, additional, Pinto, Monica, additional, Poletto, Luigina, additional, Cervo, Silvia, additional, D'Andrea, Monica, additional, Steffan, Agostino, additional, Riccardi, Gabriele, additional, Jenkins, David J A, additional, Gatti, Davide, additional, Libra, Massimo, additional, Montella, Maurizio, additional, and Augustin, Livia S A, additional

Published
2019
Full Text
View/download PDF

14. Adherence to Mediterranean Diet and Quality of Life in women treated for breast cancer (DEDiCa Study)

Author

Porciello, Giuseppe, primary, Calabrese, Ilaria, additional, Montagnese, Concetta, additional, Vitale, Sara, additional, Palumbo, Elvira, additional, Cubisino, Serena, additional, Falzone, Luca, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, Libra, Massimo, additional, Pica, Rosita, additional, De Laurentis, Michele, additional, Cavalcanti, Ernesta, additional, D'Aiuto, Massimiliano, additional, Rinaldo, Massimo, additional, Catalano, Francesca, additional, Thomas, Guglielmo, additional, Cianniello, Daniela, additional, Pacilio, Carmen, additional, Barchiesi, Vittoria, additional, Minopoli, Anita, additional, Cuomo, Marco, additional, Banna, Giuseppe, additional, Vera, Ursino, additional, Ferrau, Francesco, additional, Rossello, Rosalba, additional, Serraino, Diego, additional, Bidoli, Ettore, additional, Massarut, Samuele, additional, Guerra, Gennaro, additional, Farina, Amalia, additional, Messina, Francesco, additional, Pinto, Monica, additional, Dainotta, Patrizia, additional, Poletto, Luigina, additional, Cervo, Silvia, additional, Gallina, Stefania, additional, Steffan, Agostino, additional, Gatti, Davide, additional, Riccardi, Gabriele, additional, Jenkins, David JA, additional, Augustin, Livia SA, additional, and Montella, Maurizio, additional

Published
2019
Full Text
View/download PDF

15. Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.

Author

Buono, Giuseppe, primary, Fabi, Alessandra, additional, Del Mastro, Lucia, additional, Cannita, Katia, additional, La Verde, Nicla Maria, additional, Ardito, Raffaele, additional, Riccardi, Ferdinando, additional, Montemurro, Filippo, additional, Cazzaniga, Marina Elena, additional, Garrone, Ornella, additional, Zambelli, Alberto, additional, Conte, Benedetta, additional, Caputo, Roberta, additional, Cianniello, Daniela, additional, Bonotto, Marta, additional, Bartoletti, Michele, additional, Parola, Sara, additional, De Placido, Sabino, additional, Di Maio, Massimo, additional, and Arpino, Grazia, additional

Published
2019
Full Text
View/download PDF

16. CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.

Author

Piezzo, Michela, primary, Riemma, Maria, additional, Cianniello, Daniela, additional, Caputo, Roberta, additional, Fusco, Giuseppina, additional, Di Gioia, Germira, additional, Cerillo, Ivana, additional, Licenziato, Marina, additional, Buonfanti, Gaetano, additional, Cocco, Stefania, additional, Di Lauro, Vincenzo, additional, and De Laurentiis, Michelino, additional

Published
2019
Full Text
View/download PDF

17. Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib: Paziente con carcinoma mammario metastatico, HER2-positivo, resistente a trastuzumab e pertuzumab ma responsivo a lapatinib

Author

Cianniello, Daniela, Caputo, Roberta, Cianniello, Daniela, and Caputo, Roberta

Abstract

Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, approved for the treatment of metastatic breast carcinoma pre-treated with anti-HER2 antibodies. We report the case of a 60-year-old woman diagnosed with metastatic breast neoplasm, HER2-positive, progressing after treatment with trastuzumab, pertuzumab and T-DM1, who obtained a regression of hepatic metastases after treatment with lapatinib-capecitabine (Oncology).

Published
2018

19. PerTe: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer patients—Efficacy and safety of pertuzumab in “real life" setting.

Author

Cianniello, Daniela, primary, Prudente, Antonella, additional, Caputo, Roberta, additional, Piezzo, Michela, additional, Riemma, Maria, additional, Savastano, Beatrice, additional, Cocco, Stefania, additional, Cerillo, Ivana, additional, Lauria, Rossella, additional, Giuliano, Mario, additional, Cardalesi, Cinzia, additional, Buono, Giuseppe, additional, Arpino, Grazia, additional, Iodice, Giovanni, additional, Di Rella, Francesca, additional, Pacilio, Carmen, additional, Del Prete, Salvatore, additional, De Placido, Sabino, additional, and De Laurentiis, Michelino, additional

Published
2018
Full Text
View/download PDF

21. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study

Author

Fabi, Alessandra, primary, De Laurentiis, Michelino, additional, Caruso, Michele, additional, Valle, Enrichetta, additional, Moscetti, Luca, additional, Santini, Daniele, additional, Cannita, Katia, additional, Carbognin, Luisa, additional, Ciccarese, Mariangela, additional, Rossello, Rosalba, additional, Arpino, Grazia, additional, Leonardi, Vita, additional, Montemurro, Filippo, additional, La Verde, Nicla, additional, Generali, Daniele, additional, Zambelli, Alberto, additional, Scandurra, Giuseppa, additional, Russillo, Michelangelo, additional, Paris, Ida, additional, D'Ottavio, Anna Maria, additional, Filippelli, Gianfranco, additional, Giampaglia, Marianna, additional, Stani, Simonetta, additional, Fabbri, Agnese, additional, Alesini, Daniele, additional, Cianniello, Daniela, additional, Giannarelli, Diana, additional, and Cognetti, Francesco, additional

Published
2017
Full Text
View/download PDF

23. Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.

Author

Furlanetto, Jenny, primary, Vaccaro, Vanja, additional, Caliolo, Chiara, additional, De Laurentiis, Michele, additional, Bonomi, Maria, additional, Pilotto, Sara, additional, Massari, Francesco, additional, Nortilli, Rolando, additional, Cianniello, Daniela, additional, Cognetti, Francesco, additional, Giannarelli, Diana, additional, Tortora, Giampaolo, additional, and Bria, Emilio, additional

Published
2012
Full Text
View/download PDF

24. PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Author

D. Terribile, Emilia Marrazzo, Paola Scavina, Alessia Rognone, Lucia Vassalli, Domenico Angelucci, Patrizia Vici, Graziella Pinotti, Rossana Berardi, Francesco Cognetti, Daniele Generali, A.F. Scinto, Alessandra Fabi, Giuseppe Naso, Mario Giuliano, Giuseppe Tonini, Donatella Santini, Alberto Zambelli, Giulia Bianchi, Giovanna Catania, Maria Agnese Fabbri, Sandro Barni, Marco Colleoni, Giovanni Scognamiglio, Riccardo Masetti, Francesco Scanzi, Corrado Tinterri, Leonardo Vigna, Daniela Franco, Teresa Gamucci, Daniela Cianniello, Cognetti, Francesco, Masetti, Riccardo, Fabi, Alessandra, Bianchi, Giulia, Santini, Donatella, Rognone, Alessia, Catania, Giovanna, Angelucci, Domenico, Naso, Giuseppe, Giuliano, Mario, Vassalli, Lucia, Vici, Patrizia, Scognamiglio, Giovanni, Generali, Daniele, Zambelli, Alberto, Colleoni, Marco, Tinterri, Corrado, Scanzi, Francesco, Vigna, Leonardo, Scavina, Paola, Gamucci, Teresa, Marrazzo, Emilia, Scinto, Angelo Fedele, Berardi, Rossana, Fabbri, Maria Agnese, Pinotti, Graziella, Franco, Daniela, Terribile, Daniela Andreina, Tonini, Giuseppe, Cianniello, Daniela, and Barni, Sandro

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, Population, MEDLINE, Predictive markers, Article, 03 medical and health sciences, breast cancer, Breast cancer, 0302 clinical medicine, real life, Internal medicine, Cancer genomics, medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, early stage, education, RC254-282, education.field_of_study, Chemotherapy, medicine.diagnostic_test, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Hormonal therapy, Observational study, business, Oncotype DX, Adjuvant
Abstract

Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.

Published
2021

25. Gene expression assay in the management of early breast cancer

Author

Roberta Caputo, Maria Antonietta Riemma, Michelino De Laurentiis, Michela Piezzo, Daniela Cianniello, Marco Trovo, Massimiliano Berretta, Antonio Giordano, Caputo, Roberta, Cianniello, Daniela, Giordano, Antonio, Piezzo, Michela, Riemma, Maria, Trovo, Marco, Berretta, Massimiliano, and De Laurentiis, Michelino

Subjects
Oncology, medicine.medical_treatment, Biochemistry, PAM50/Prosigna, Oncotype DX, 0302 clinical medicine, MammaPrint, Drug Discovery, Health care, Receptors, Gene Expression Assay, Adjuvant, 0303 health sciences, MapQuant Dx, medicine.diagnostic_test, Management of Early Breast Cancer, Gene Expression Regulation, Neoplastic, Receptors, Estrogen, Local, Chemotherapy, Adjuvant, MammaPrint dx, 030220 oncology & carcinogenesis, Molecular Medicine, Hormonal therapy, medicine.medical_specialty, medicine.drug_class, Breast Neoplasms, +, ), 03 medical and health sciences, Adjuvant chemotherapy, Early breast cancer (EBC), Estrogen receptor positive (ER, Diagnostic Tests, Routine, Gene Expression Profiling, Humans, Neoplasm Recurrence, Local, Diagnostic Tests, Internal medicine, Breast Cancer, medicine, Endocrine system, Chemotherapy, Routine, Adverse effect, 030304 developmental biology, Pharmacology, Neoplastic, business.industry, Organic Chemistry, Estrogen, Neoplasm Recurrence, Gene Expression Regulation, business
Abstract

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).

Published
2020

26. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results

Author

Michelino De Laurentiis, Dario Bruzzese, Roberta Caputo, Ferdinando Riccardi, Andrea Michelotti, Mariavittoria Locci, Vito Lorusso, Fabio Puglisi, Marta Bonotto, Claudia von Arx, Mariangela Ciccarese, Francesco Schettini, Domenico Bilancia, Sabino De Placido, Grazia Arpino, Daniela Cianniello, Alessandra Fabi, Giuseppe Buono, Bianca Maria Veneziani, Mario Giuliano, De Placido, Sabino, Giuliano, Mario, Schettini, Francesco, VON ARX, Claudia, Buono, Giuseppe, Riccardi, Ferdinando, Cianniello, Daniela, Caputo, Roberta, Puglisi, Fabio, Bonotto, Marta, Fabi, Alessandra, Bilancia, Domenico, Ciccarese, Mariangela, Lorusso, Vito, Michelotti, Andrea, Bruzzese, Dario, Veneziani, Bianca Maria, Locci, Mariavittoria, De Laurentiis, Michelino, and Arpino, Grazia

Subjects
0301 basic medicine, Oncology, Receptor, ErbB-2, Docetaxel, Clinical practice, law.invention, Breast cancer, 0302 clinical medicine, Randomized controlled trial, Trastuzumab, law, Observational study, Antineoplastic Combined Chemotherapy Protocols, Medicine, skin and connective tissue diseases, Randomized Controlled Trials as Topic, Aged, 80 and over, education.field_of_study, General Medicine, Middle Aged, HER2, Paclitaxel, Pertuzumab, Real life, Surgery, Metastatic breast cancer, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, Female, Taxoids, medicine.drug, Adult, Bridged-Ring Compounds, medicine.medical_specialty, Population, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Internal medicine, Humans, education, Aged, Retrospective Studies, Taxane, business.industry, Retrospective cohort study, medicine.disease, 030104 developmental biology, business
Abstract

Objectives Given their inclusion and exclusion criteria, randomized clinical trials (RCT) might not include a population that truly mirrors real life (RL). This raises concerns about the applicability of RCT results in clinical practice. We evaluated the efficacy of anti-HER2 treatment with pertuzumab combined with trastuzumab and a taxane as first-line treatment for HER2-positive metastatic breast cancer in a RL setting, and compared the safety results obtained in our population versus the experimental cohort of the CLEOPATRA RCT, which led to the approval of this therapy. Materials and methods Patients treated with trastuzumab, pertuzumab and a taxane were enrolled in this retrospective study. We compared the tumor features and the patients' characteristics of the RL cohort to those of the CLEOPATRA cohort. We also compared the median progression-free survival (PFS) in the RL population versus specific patients' subgroups. Results RL patients were more frequently HR-positive, less likely to have visceral metastases (P

Published
2018

27. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study

Author

Daniele Santini, Simonetta Stani, Alberto Zambelli, Alessandra Fabi, Vita Leonardi, Michelangelo Russillo, Daniele Alesini, Daniela Cianniello, Grazia Arpino, Luisa Carbognin, Diana Giannarelli, Michele Caruso, Marianna Giampaglia, Mariangela Ciccarese, Giuseppa Scandurra, Daniele Generali, Rosalba Rossello, E. Valle, A. Fabbri, Gianfranco Filippelli, Filippo Montemurro, Ida Paris, Katia Cannita, Luca Moscetti, Nicla La Verde, A.M. D'Ottavio, Michelino De Laurentiis, Francesco Cognetti, Fabi, Alessandra, DE LAURENTIIS, Michelino, Caruso, Michele, Valle, Enrichetta, Moscetti, Luca, Santini, Daniele, Cannita, Katia, Carbognin, Luisa, Ciccarese, Mariangela, Rossello, Rosalba, Arpino, Grazia, Leonardi, Vita, Montemurro, Filippo, La Verde, Nicla, Generali, Daniele, Zambelli, Alberto, Scandurra, Giuseppa, Russillo, Michelangelo, Paris, Ida, D'Ottavio, Anna Maria, Filippelli, Gianfranco, Giampaglia, Marianna, Stani, Simonetta, Fabbri, Agnese, Alesini, Daniele, Cianniello, Daniela, Giannarelli, Diana, Cognetti, Francesco, De Laurentiis, Michelino, and D’Ottavio, Anna Maria

Subjects
musculoskeletal diseases, 0301 basic medicine, Oncology, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, medicine.medical_treatment, Population, ado-trastuzumab emtansine, HER2, metastatic breast cancer, taxane, trastuzumab, Lapatinib, Metastasis, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, Internal medicine, medicine, skin and connective tissue diseases, education, neoplasms, education.field_of_study, Taxane, business.industry, Cancer, medicine.disease, Metastatic breast cancer, 030104 developmental biology, 030220 oncology & carcinogenesis, Clinical Research Paper, business, medicine.drug
Abstract

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (mBC). The aim of this ‘field-practice’ study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2-positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions. One hundred fourty-nine (49%) and 264 (87%) had received prior hormonal treatment and/or anti-HER2 targeted therapy, respectively. Particularly, 149 patients had been previously treated with lapatinib. The objective response rate (ORR) was 36.2%, and 44.5% when T-DM1 was administrated as second-line therapy. Considering only patients with liver metastases, the ORR was 44.4%. The median progression-free survival (PFS) was 7.0 months in the overall population, but it reached 9.0 and 12.0 months when TDM-1 was administered as second- and third-line treatment, respectively. In conclusion, in this ‘real-word’ study evaluating the effects of T-DM1 in patients with HER2-positive mBC who progressed on prior anti-HER2 therapies, we observed a clinically-relevant benefit in those who had received T-DM1 in early metastatic treatment-line and in subjects previously treated with lapatinib.

Published
2017

28. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report

Author

Roberta Caputo, Daniela Cianniello, Michelino De Laurentiis, Caputo, Roberta, Cianniello, Daniela, and De Laurentiis, Michelino

Subjects
Oncology, Cancer Research, Pleural effusion, Comorbidity, taxane, Antineoplastic Agent, chemistry.chemical_compound, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Neoplasm Metastasis, eribulin, General Medicine, Ketones, Middle Aged, Ketone, Metastatic breast cancer, Combined Modality Therapy, Neoplasm Metastasi, Treatment Outcome, 030220 oncology & carcinogenesis, Retreatment, Female, metastatic breast cancer, Breast Neoplasm, Human, Eribulin, Eribulin Mesylate, medicine.medical_specialty, Disease Response, Anthracycline, Antineoplastic Agents, Breast Neoplasms, anthracycline, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Biomarkers, Tumor, Furan, Humans, Furans, Antineoplastic Combined Chemotherapy Protocol, Taxane, business.industry, medicine.disease, chemistry, business
Abstract

Anthracycline- or taxane-based regimens are commonly used in the treatment of breast cancer, often in the (neo)adjuvant and first-line metastatic settings. However, to date, there is no single accepted standard of care after failure of these cytotoxic agents. Following the promising results obtained in the Phase III EMBRACE study, eribulin mesylate was approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes unless contraindications. This case report describes a chemo-pretreated woman with important pleural effusion, nodal, locoregional involvement from breast cancer who had a disease response after treatment with eribulin in second line. This case underlines how this well-tolerated monochemotherapy may be able to obtain a prolonged disease control and a good clinical outcome.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results